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Edited by Beat ImhofAbstract Using a signal sequence trap for selection of diﬀer-
entially expressed secretory and membrane proteins, we identi-
ﬁed a novel member of the adhesion family of G-protein coupled
receptors (GPCRs), termed vascular inducible GPCR (VIGR).
VIGR contains C1r-C1s, Uegf and Bmp1 (CUB) and pentraxin
(PTX)-like modules and a mucin-like spacer, followed by seven
transmembrane domains. By surface biotinylation as well as by
immunoﬂuorescence analysis we demonstrate that endogenous,
highly glycosylated VIGR is expressed on the cell surface of
endothelial cells (ECs) upon LPS or thrombin treatment, and
inducible expression is mediated by MAP kinases, but not NF-
jB. We show that VIGR is selectively expressed in ECs derived
from larger vessels, but not from microvessels. In summary,
VIGR represents a novel GPCR of the adhesion family, which is
unique in its long extra-cellular domain comprising CUB and
PTX-like modules and in its inducibility by LPS and thrombin in
a subset of ECs, suggesting an important function in cell-
adhesion and potentially links inﬂammation and coagulation.
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by Elsevier B.V. All rights reserved.
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The vascular endothelium is located at the interface between
the bloodstream and the body tissues and plays an active and
central role in the process of acute inﬂammation by controlling
the transmigration of leukocytes through the EC layer and the
ﬂux into an inﬂammatory nidus [1]. Many of the proteins in-
volved are either up- or down-regulated in response to pro-
inﬂammatory stimuli, including cytokines, secreted proteases
and receptors.
G-protein coupled receptors (GPCRs) represent the most
diverse protein family in structure as well as in function [2] and
couple to second messenger cascade mechanisms, such as cyclic
AMP, inositol phosphate, calcium ions, or diacylglycerol,
through heterotrimeric G proteins, though, signals may be also
transmitted via other, non G-protein eﬀector molecules [2,3].
GPCRs can process a wide variety of exogenous stimuli in-
cluding hormones, cytokines, peptides, amino acid derivates,
ions, neurotransmitters and sense dependent stimuli to mediate
signal transduction. Altogether ﬁve families of GPCRs can be
distinguished, including glutamate, rhodopsin, adhesion, friz-
zled/taste2, and secretin, accordingly to the GRAFS classiﬁ-
cation system [4].
The steadily growing family of adhesion GPCRs (formerly
known as secretin-like, B2, EGF-TM7, LNB-7TM, or LN-
7TM), are intriguing receptors with evidence of participation in
lymphocyte activation, macrophage biology, synaptic exocy-
tosis and planar polarization during organogenesis [5–7]. Re-
cent evidence suggests that at least 30 family members are
encoded in the human genome [8]. These receptors are char-
acterized, besides their heptahelical domain, by the presence of
a long extracellular domain built of adhesion motifs, such as
EGF, cadherin, lectin, laminin, olfactomedin, immunoglobu-
lin, integrin-binding, or thrombospondin domains, a highly
glycosylated, proline-rich mucin-like region that is linked to the
heptahelical domain via the GPCR proteolytic site (GPS) [5–7].
Proteolytic cleavage of the GPS might result in shedding of the
receptor from the plasma membrane giving raise to a soluble
a-subunit, which is non-covalently linked to the b-subunit
comprised of the heptahelical domain and the cytoplasmic tail
[9–14]. Also the conserved cysteine residues localized in the ﬁrst
and second extracellular loop that apparently form a disulﬁde
bond to stabilize the tertiary structure, are found in the adhe-
sion class of GPCRs. Receptors of this family, such as CD97
and EMR2-4 have indeed been shown to bind to other cell
surface proteins and extracellular matrix proteins via their
adhesion modules in the extracellular domain [11,15–20]. Toblished by Elsevier B.V. All rights reserved.
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stimuli and the mechanisms underlying the resulting intercel-
lular cross talk, we were interested in diﬀerentially expressed
secretory and membrane proteins in activated ECs, which we
selected using a novel signal sequence trap.2. Materials and methods
2.1. Vector construction and functional screen for signal sequences and
transmembrane domains
Plasmids pAP1, pAP2, and pAP3 were constructed using pTrc99A
(Roche) and pMG [21]. These plasmids contain a signal sequence de-
leted form of the bacterial alkaline phosphatase A encoding gene AP
[21] and a multiple cloning site in all three reading frames. cDNA li-
braries derived from human umbilical vein ECs (HUVECs) were am-
pliﬁed by PCR and cloned in all three reading frames into pAP1-3.
Escherichia coli DH5a were transformed by electroporation using
Gene Pulser (Bio-Rad) at 25 lF/200 X/1.5 kV and 0.1 cm electrode gap
cuvettes (Bio-Rad) and were selected with 50 lg/ml ampicillin, 100 mM
isopropyl-b-D-thiogalactopyranoside, and 40 lg/ml 5-bromo-4-chloro-
3-indolyl-phosphate (XGAL). Bacterial colonies, which express an AP
gene with a functionally restored signal sequence, were detected when
growing in presence of the chromogenic AP-substrate XGAL. Positive
clones were analyzed by DNA sequencing.
2.2. Northern-, Southern-, and dot-blot hybridization
Hybridizations were carried out using QuickHyb solution (Strata-
gene) under high stringent conditions according to the manufacturers
instructions and signals were analyzed on a PhosphoImager SF (Mo-
lecular Dynamics). Total RNA and genomic DNA were isolated using
Trizol reagent (Gibco-BRL) and mRNA was isolated using Dynabe-
ads (Dynal). cDNA probes and mRNAs were labeled by random
priming (Stratagene) and reverse transcription (Roche) in the presence
of [a-32P]dATP, respectively.
2.3. Cell culture and metabolic labeling of cells
Human ECs were grown in gelatin-coated ﬂasks in M199-medium/
20% SCS (HyClone)/endothelial cell growth factor supplement
(ECGF) (Technoclone, Vienna, Austria)/Penicillin/Streptomycin/Fun-
gizone (Bio Whittaker)/3 U/ml heparin (Roche). Where indicated cells
have been treated with LPS (lipopolysaccharide, 600 ng/ml), TNFa
(tumor necrosis factor a, 500 U/ml), CHX (cycloheximide, 10 lg/ml),
IL-1b (Interleukin-1b, 300 U/ml), IL-6 (200 U/ml), IL-8 (200 ng/ml),
IL-10 (2 ng/ml), EGF (epidermal growth factor, 10 ng/ml), TGFb
(transforming growth factor b, 2 ng/ml), thrombin (4 U/ml), VEGF
(vascular endothelial growth factor, 1.25 nM), OM (oncostatin M, 20
ng/ml), PMA (phorbol 12-myristate 13-acetate, 20 ng/ml), or IF-a
(interferon-a, 1000 U/ml). HUVECs were metabolically labeled with
50 lCi/ml Pro-mix L-[35S] (Amersham–Pharmacia Biotech) in Cys/
Met-deﬁcient RPMI 1640 medium (Gibco-BRL) supplemented with
5% SCS (HyClone)/ECGF (Technoclone, Vienna, Austria)/Penicillin/
Streptomycin/Fungizone (Bio Whittaker)/heparin (3 U/ml, Roche) for
16 h. All batches of ECs were tested routinely for their inducibility in
response to pro-inﬂammatory stimuli, employing an ELAM-1 ELISA
test.
2.4. cDNA cloning and sequencing
HUVEC and placenta lambda cDNA libraries (Clontech) were
screened with a 300 bp [a-32P]dATP labeled cDNA probe (prime-it II,
Stratagene) speciﬁc to the heptahelical domain of vascular inducible
GPCR (VIGR) using QuickHyb solution (Stratagene) at 65 C ac-
cording to the manufacturer’s instructions, and a 1.3 kb cDNA was
identiﬁed. This cDNA fragment was elongated by 30 and 50 RACE
methods. A list of primers is given in the on-line supplement. Obtained
PCR fragments were cloned into pGEM vectors (Promega) and se-
quenced using the ABI PRISM system and a 373A DNA sequencer
(both Perkin–Elmer).
2.5. Generation and aﬃnity-puriﬁcation of polyclonal antibodies
A recombinant VIGR protein, comprised of a part of the extracel-
lular domain (7TM: aa 625-745) in pQE31 (Qiagen), was expressed and
puriﬁed from E. coli M15 (Qiagen) as a 6 His-tagged fusion protein.Branched peptides (P3: WGPPDISNCSREA, aa 544–556; P4:
GLPSNNESY, aa 671–679; C1: VKGYCNAHSDNFYK, aa 1195–
1208; C2: GRFRLADNSDWSKT, aa 1104–1117) were synthesized
(Research Genetics) and either 225 lg of these branched, unconjugated
peptides without a carrier protein or 100 lg of the 6 His-fusion
protein were directly used for immunization of rabbits with Complete
Freund’s adjuvant and three times booster immunizations in 4 week
intervals using Incomplete Freund’s adjuvant. The resulting antisera
were aﬃnity-puriﬁed using either the immobilized peptides or the fu-
sion protein. For immunoprecipitation experiments, 2–3 lg of puriﬁed
antibodies (C2 or 7TM) were used. In immunoﬂuorescence studies, the
P4 antibody was applied at a concentration of 5 lg/ml.
2.6. Biotinylation of cell surface proteins and immunoprecipitation
To biotinylate cell surface proteins, cells were washed with ice-cold
PBS and incubated with 0.5 mg/ml of Sulfo-NHS-LC-Biotin (Pierce) in
PBS for 40 min at 4 C. Cells were washed and lysed using 1% sucrose
monolaurate buﬀer (150 mMNaCl/5 mMMgCl2/50 mM Tris/HCl, pH
7.5/20 lg/ml PMSF) and cleared by centrifugation. 300 lg or 107 cpm
of protein lysate were pre-cleared with Protein A–Sepharose at 4 C for
30 min and immunoprecipitated at 4 C o/n. Immune complexes were
washed three times with 0.2% NP-40/10 mM Tris, pH 7.5/150 mM
NaCl/2 mM EDTA, twice with 0.2% NP-40/10 mM Tris, pH 7.5/500
mM NaCl/2 mM EDTA, once with 10 mM Tris pH 7.5 and analyzed
by SDS–PAGE followed by either autoradiography or immunoblot-
ting using streptavidin–peroxidase conjugate (Roche) and ECL plus
(Amersham–Pharmacia Biotech).
2.7. Treatment of HUVECs with chemical inhibitors
HUVECs were treated with LPS alone or in combination with either
5 lM of the speciﬁc nuclear factor kappaB (NF-jB) inhibitor BAY11-
7082 (Alexis), 50 lM of the speciﬁc MEK1 inhibitor PD98059 (Tocris),
40 lM of the speciﬁc p38 MAPK inhibitor SB202190 (Tocris), or 25
lM of the speciﬁc JNK inhibitor SP600125 (Tocris) for 16 h. Inhibitors
were added to the culture medium 1 h prior to LPS stimulation. Bio-
tinylation and immunoprecipitation was carried out as described
above.
2.8. Deglycosylation by tunicamycin treatment
Where indicated, HUVECs were treated with LPS and 4 lg/ml tu-
nicamycin (Roche) for 16 h.
2.9. Immunoﬂuorescence
HUVECs were grown on ﬁbronectin (Sigma) coated Permanox
chamber slides (Lab-Tek), treated with LPS for 16 h or left untreated,
then washed with PBS supplemented with 0.5% FBS and 0.1% BSA
and stained with an indirect labeling method by incubating ﬁrst with
the aﬃnity puriﬁed anti-VIGR-P4 antibody in 0.1% BSA in PBS at 4
C for 2 h, washed and stained with a FITC-anti-rabbit secondary
antibody (Molecular Probes). Stained cells were then ﬁxed with 70%
ethanol at 4 C o/n. Following washing three times with ice-cold PBS,
slides were mounted and visualized under a ﬂuorescence microscope.
2.10. ELAM-1 ELISA
HUVECs were seeded into 96-well plates and conﬂuent cell layers
were stimulated with LPS for 4 h. Cells were ﬁxed using 0.1% glutar-
aldehyde for 15 min at 4 C and subsequently incubated in 5% BSA for
1 h. ELAM-1 expression is detected by using anti-ELAM-1 antibody
(R&D Systems) and a goat anti-mouse-HRP conjugate (Amersham–
Pharmacia). After incubation with OPD substrate (Sigma), the reac-
tion was stopped by addition of H2SO4 and absorption by 492 nm was
measured. All samples were done in duplicates.3. Results
3.1. Molecular cloning of VIGR, a novel member of the
adhesion class of the GPCR super-family
We employed a two-step signal sequence trap procedure to
identify diﬀerentially expressed secretory and transmembrane
proteins in endothelial cells (ECs) (C. Stehlik, B.R. Binder, and
J. Lipp, manuscript submitted). First, cDNAs were screened
Fig. 1. Dot-blot analysis of VIGR cDNA. Bacterial colonies were
grown on nylon membranes and hybridized to reverse transcribed, [a-
32P]dATP labeled mRNA isolated from either resting or 12 h LPS-
treated HUVECs. Colonies containing b-actin cDNA-fragments were
used as control.
Fig. 2. (A) The hydropathy proﬁle of human VIGR according to Kyte
and Doolittle. Signal sequence (ss), transmembrane domain (TM). (B)
Percentage of amino acid identity and similarity for human, mouse and
rat VIGR proteins.
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sequence function, employing pAP plasmids as a vector.
Bacterial alkaline phosphatase A (AP) lacking its signal se-
quence was used as a reporter gene to identify cDNA frag-
ments that can restore signal sequence function, employing a
chromogenic AP-substrate. In a second step we screened the
candidate genes whether they are diﬀerentially expressed in
response to pro-inﬂammatory stimuli in ECs by dot-blot
analysis (Fig. 1). Selected bacteria were grown on grid-
containing agar plates, transferred to nylon membranes and
hybridized with 32P-labelled cDNA derived from resting or
LPS-stimulated HUVECs.
One of the identiﬁed proteins was VIGR, showing similarity
to the adhesion GPCRs, which are believed to be involved in
cell adhesion [5–7]. The full-length cDNA of 4.7 kb encodes an
open reading frame of 1222 amino acids and a deduced protein
of 136 kDa. A hydropathy proﬁle of VIGR predicted a hy-
drophobic signal sequence at the N-terminus and seven trans-
membrane-spanning domains at the C-terminus (Fig. 2A). The
highest overall identity of 39% and 31% was found to HE6 and
CD97, respectively [22,23]. Amino acid sequence analysis re-
vealed all the characteristics of the adhesion class of GPCRs,
including a signal peptide, a long, highly glycosylated extra-
cellular domain with 27 putative N-glycosylation sites, and a
GPS. Within the heptahelical domain two conserved cysteine
residues are present, which are thought to form a disulﬁde
bridge between the ﬁrst and second extracellular loop that have
been shown to be critical for the function of the secretin re-
ceptor [24]. When compared to other family members of the
adhesion class of GPCRs, two not yet documented protein
motifs are found in the extracellular portion, namely a C1r-C1s,
Uegf and Bmp1 (CUB) (aa residues 41–149) and a pentraxin
(PTX)-like (aa residues 150–355) domain. Two cysteine resi-
dues forming a potential palmitoylation site are found in the
long cytoplasmic domain which also contains several potential
phosphorylation sites for cAMP dependent kinases/protein
kinase G, protein kinase C, casein kinase II, as well as a po-
tential myristoylation signal and a microbodies C-terminal
targeting motif.Predicted VIGR orthologues are encoded in the mouse
(XM136924) and rat (XM218313) genome, sharing between
69% and 78% identity, and between 73% and 80% similarity,
respectively (Fig. 2B).3.2. Chromosomal localization, genomic organization and tissue
distribution of VIGR
Southern-blot analysis of human genomic DNA revealed a
single copy gene that wemapped to chromosome 6 by Southern-
blot analysis of a PstI digested Somatic Cell Hybrid Panel
(Oncor) (Fig. 3A and data not shown). A 135 kb (AL033377)
genomic sequence of chromosome 6q23.1–24.3 revealed that the
VIGR gene is organized in 24 exons spanning 133.9 kbp of ge-
nomic DNA (Fig. 3B). By sequence analysis and comparison to
the human genome, the genomic structure of VIGRwas veriﬁed
and the intron/exon boundaries were determined (Fig. 3C). All
introns are ﬂanked by the splicing consensus sequences, GT at
the start and AG at the end of the intron. Similarly, mouse and
rat vigr are encoded in 23 exons spanning 69,4 kbp on band A2
on the syntenic mouse chromosome 10, and 64 kbp on the
syntenic rat chromosome 1p13, respectively. However, in
mouse and rat, the signal peptide is encoded in just two exons,
thus missing exon 2. Northern-blot analysis revealed three
VIGR transcripts of approximately 4.7, 7.7, and 9 kb in placenta
and to a lower extent in pancreas and liver (Fig. 3D). These
transcripts most likely represent alternatively spliced iso-forms
or utilization of alternative polyadenylation signals.
3.3. Expression of VIGR is EC-type speciﬁc and inducible
We identiﬁed VIGR as a diﬀerentially expressed gene in
activated primary human ECs, therefore we tested the ex-
pression in response to a variety of inﬂammatory stimuli. In
HUVECs, VIGR responded to LPS and thrombin, but not to
other inﬂammatory stimuli, with clearly elevated mRNA levels
detectable after 4 h, peaking at 12 h, and declining to back-
ground levels at 24 h of LPS treatment (Fig. 4A). When we
performed similar time course experiments using primary ECs
of diﬀerent origin we could not detect any transcripts in skin
microvascular ECs (Fig. 4B, right panel). However, constitu-
tive expression of the 4.7 kb transcript was detectable in aortic
ECs (Fig. 4C). The discrepancy between inducibility of VIGR
expression in skin-microvascular derived ECs to umbilical vein
derived ECs was also observed in EC lines generated by in-
fection with an amphotrophic helper free recombinant retro-
virus construct, pLXSN16 E6/E7, containing the E6/E7 open
reading frame of human papilloma virus 16 (personal gift,
Renate Hofer-Warbinek). None of the skin microvascular EC
derived lines, named HM2, HM39/2, and HM60, were found
to express VIGR in response to LPS stimulation (data not
shown), whereas the HUVEC derived line HU2 was able to
express VIGR upon LPS stimulation (data not shown). Results
obtained by Northern-blot analysis were similar to the results
shown in Fig. 4 for the primary cells. All these cell lines were
tested positively for expression of adhesion molecules upon
pro-inﬂammatory stimuli, the ability of tube formation and
LDL uptake and reﬂect typical endothelial cell behaviour
regarding these aspects.
3.4. VIGR is a highly glycosylated cell surface protein
To analyze VIGR protein, we raised polyclonal rabbit
antibodies either directed to the extracellular- (P3,P4),
Fig. 3. Genomic organization of VIGR. (A) Southern blot of human genomic DNA, digested with either PstI,HinDIII, or EcoRI and hybridized with
a cDNA speciﬁc to VIGR. (B) Human VIGR genomic organization. ED (extracellular domain), TM (transmembrane domain), CD (cytoplasmic
domain), ss (signal sequence). An asterisk indicates the stop codon in human exon 24. (C) Intron/exon organization of human VIGR. Size of introns
and exons as well as the cDNA position of exons are indicated. In addition, the sequence surrounding the intron–exon boundaries are shown,
highlighting the conserved GT at the 50end and the conserved AG at the 30 end of the introns. Data were generated by aligning the VIGR cDNA
sequence to the human genome sequence covering the long arm of chromosome 6. (D) Tissue distribution of VIGR mRNA. A multiple human tissue
Northern-blot (Oncor) was hybridized with a 32P labeled cDNA probe encoding VIGR. A RNA size marker is indicated on the left.
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Immunoprecipitation of metabolically labeled and LPS treated
HUVECs revealed a 230 kDa protein which was speciﬁcally
recognized. None of the antibodies recognized speciﬁc proteins
in non-stimulated HUVECs. The diﬀerence in size to the
predicted molecular weight of 136 kDa is probably due to
extensive glycosylation of the extracellular domain, which was
conﬁrmed by treatment of HUVECs with tunicamycin, a
potent inhibitor of N-glycosylation, resulting in a reduced
molecular weight of 136 kDa (Fig. 5A).
To demonstrate that VIGR is indeed expressed on the cell
surface, we biotinylated surface proteins on HUVECs. Total
protein lysates were immunoprecipitated and immune com-
plexes were analyzed by SDS–PAGE/immunoblotting using
streptavidin–peroxidase conjugates speciﬁc for biotinylated
proteins. The 230 kDa VIGR protein was detected on the cell
surface of LPS stimulated HUVECs, and pretreatment with
tunicamycin reduced the molecular weight to 136 kDa. No
protein was detected on the surface of resting HUVECs (Fig.
5B). Moreover, the presence of under- or non-glycosylated
forms at the cell surface shows that glycosylation is not es-sential for the cellular localization and seems not to impair
intracellular transport of VIGR. VIGR expression on the cell
surface of HUVECs is dose-dependent. Highest expression is
detected using 600 ng/ml LPS in the medium, but 100 ng
LPS are suﬃcient to induce VIGR expression. In contrast to
VIGR, the LPS dependent expression of the EC activation
marker ELAM-1 was constant under these experimental set-
tings (Fig. 5C).
Additionally, we visualized VIGR expression on the cell
surface by immunostaining of LPS stimulated HUVECs with
VIGR antibodies, which recognize the extracellular domain of
VIGR and a FITC-labeled secondary antibody. Immunoﬂuo-
rescence analysis showed cell membrane expression of VIGR
(Fig. 6A and B), however, no staining was detected in quies-
cent HUVECs (Fig. 6C and D).
3.5. Activation of mitogen-activated protein kinases (MAPKs),
but not NF-jB results in inducible expression of VIGR in
HUVECs
In order to delineate the signaling pathways that are re-
sponsible for the inducible expression of VIGR in HUVECs,
Fig. 5. Immunoprecipitation of VIGR. (A) HUVECs were metaboli-
cally labeled for 16 h in the presence of LPS (lane 2) or LPS and 4 lg/
ml tunicamycin (lane 3). Total lysates were subjected to immunopre-
cipitation with anti-VIGR antibodies (C2) and bound immune com-
plexes were separated by SDS–PAGE and detected by ﬂuorography. A
14C-labeled molecular weight standard is shown in lane 1. (B) Resting
(lane 1) or 16 h LPS treated HUVECs in absence (lane 2), or presence
of 4 lg/ml tunicamycin (lane 3), were surface biotinylated and sub-
jected to immunoprecipitation using C2 antiserum. Immune complexes
were separated by SDS–PAGE and analyzed by immunoblotting with
streptavidin–peroxidase complexes. (C) Dose-dependent expression of
VIGR on the cell surface of HUVECs in response to LPS. HUVECs
were either left untreated, or were treated with 100, 300 and 600 ng/ml
LPS for 16 h, and analyzed as above by surface biotinylation and
immunoprecipitation [left panel]. For comparison, ELAM expression
was determined by ELISA after stimulation with 0, 100, 300, and 600
ng/ml LPS for 4 h [right panel]. VIGR proteins are marked by arrows.
All cell lysates were normalized for protein content.
Fig. 6. Localization of VIGR in HUVECs. (A,B) HUVECs were either
treated with LPS for 16 h or (C,D) left untreated. HUVECs were
analyzed for VIGR expression using P4 antiserum and a FITC-labeled
anti-rabbit secondary antibody. Cells were visualized directly by
ﬂuorescence microscopy (A,C), or by phase contrast (B,D).
Fig. 4. VIGR expression in ECs. (A) Northern-blot analysis using total
RNA isolated from HUVECs, treated for 9 h with the indicated stimuli
(left panel) and a time course of VIGR expression in response to LPS
(0, 4, 9, 12, and 24 h) (right panel). (B) An identical experiment was
performed in human skin microvascular ECs (HSMECs). (C) VIGR
mRNA expression in HAECs treated with LPS or TNFa for 8 h. A
cDNA speciﬁc to human GAPDH was used simultaneously as a con-
trol. VIGR and GAPDH transcripts are indicated by arrows.
Fig. 7. Expression of VIGR on the cell surface in response to LPS is
dependent on the combined activation of MAPK pathways. (A) HU-
VECs were either left untreated (lane 1) or were treated with LPS (200
ng/ml) for 16 h (lanes 2–7). Where indicated, speciﬁc chemical kinase
inhibitors were applied 1 h prior to LPS treatment. Proteins were then
surface biotinylated and VIGR was immunoprecipitated as described.
NF-jB activation was inhibited with 5 lM of BAY11-7082 (lane 3);
p38 activation was blocked with 40 lM of SB202190 (lane 4); activa-
tion of JNK was inhibited with 25 lM of SP600125 (lane 5); and
MEK1 activation was blocked with 50 lM PD98059 (lane 6). As a
speciﬁcity control, C2 pre-immune serum was employed in lane 7 in the
immunoprecipitation step. (B) HUVECs were treated as above, but
LPS treatment was reduced to 4 h to measure ELAM-1 expression by
ELISA under these conditions. All cell lysates were normalized for
protein content.
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jB. We treated cells simultaneously with LPS and either the
speciﬁc NF-jB inhibitor BAY11-7082, the speciﬁc MEK1 in-
hibitor PD98059, the speciﬁc p38 MAPK inhibitor SB202190,
or the speciﬁc JNK inhibitor SP600125 for 16 h. Cell surface
proteins were then speciﬁcally biotinylated and immunopre-
cipitation was performed as described above. Surprisingly,
inhibition of the major pro-inﬂammatory transcription factor
154 C. Stehlik et al. / FEBS Letters 569 (2004) 149–155NF-jB did not aﬀect the inducibility of VIGR in response to
LPS (Fig. 7, lane 3). However, speciﬁc inhibition of JNK and
MEK1 (Fig. 7, lanes 5 and 6), but not p38 (Fig. 7, lane 4)
MAPK pathways completely abolished VIGR expression in
response to LPS in HUVECs (Fig. 7A). As a control, we de-
termined expression of EC-speciﬁc adhesion molecule of the
selectin family ELAM-1, a known NF-jB target gene, by
ELISA under identical conditions. This adhesion molecule is
tightly regulated in ECs and cytokine inducibility requires the
co-operative interaction of NF-jB, ATF-2 and high mobility
group I protein (Y) transcription factor complexes [25]. It was
recently suggested that the ELAM promoter also contains an
inducible AP-1/CREB site [26]. As shown in Fig. 7B, ELAM-1
expression is most sensitive to the NF-jB inhibitor BAY11-
7082, whereas MAPK inhibitors are less potent in inhibiting
ELAM-1 expression in HUVECs upon LPS treatment.4. Discussion
We established a novel method for fast, simple and selective
cloning of diﬀerentially expressed genes encoding secretory or
membrane proteins. Using this approach we identiﬁed a novel
cell surface receptor on ECs, which belongs to the adhesion
family of GPCRs.
Most of the human adhesion GPCR family members are
closely related on genetic level and found within the paralogon-
3, which contains chromosomes 1/5p–q21/6p21–p25/9/15q11–
q26/19p [4]. Moreover, the heptahelical region is formed by ﬁve
exons instead of eight exons as usually found in the related
secretin family of GPCRs. The heptahelical domain of VIGR is
organized by ﬁve exons and localizes to paralogon-3.
Expression of VIGR varies with the type and origin of ECs.
ECs derived from the microvasculature did not express VIGR.
However, human aortic ECs (HAECs) showed constitutive
basal expression and HUVECs displayed inducible expression
in response to LPS and thrombin. This is of special note con-
sidering that LPS and thrombin may induce a large number of
genes and complex cellular responses in ECs derived from large
and small vessels [27]. Thrombin, a central protease of the co-
agulation pathway, initiates the ﬁnal step in conversion of ﬁ-
brinogen to ﬁbrin and activates platelets to form a clot [28].
Increasing evidence suggests that the innate immune response
and the coagulation system have coevolved and continue to
function as highly integrated systems in response to injury and
infection. Systemic inﬂammation is a potent pro-thrombotic
stimulus by down-regulating anti-coagulant factors and in-
hibiting ﬁbrin formation, while up-regulating pro-coagulant
mediators and increasing platelet activity [29]. Moreover, acute
inﬂammation occasionally results in systemic activation of the
coagulation system, referred to as disseminated intravascular
coagulation [27]. In addition of preventing thrombosis, anti-
coagulatory factors also display an anti-inﬂammatory activity
[30]. Apart from this, thrombin regulates expression of genes
mediating mitogenesis, adhesion to leukocytes, and hemostasis
[31]. Although genes induced by LPS or thrombin are rather
diverse and cell type dependent, there is a subset of genes that
can be induced by both stimuli. However, diﬀerent signaling
pathways are involved [31,32]. LPS mediated activation of NF-
jB occurs through the toll-like receptor 4 complex, whereas
thrombin acts through the activation of protease activated re-
ceptors. Most of the genes aﬀected are mediators of the in-ﬂammatory response, controlled by NF-jB, which plays a
pivotal role in activated ECs. Therefore, we conducted initial
experiments using a recombinant adenovirus encoding inhibi-
tor of NF-jB (IjBa) [33,34]. Ectopic expression of IjBa (data
not shown), as well as inhibition of NF-jB activation em-
ploying chemical inhibitors, did not impair LPS induced ex-
pression of VIGR suggesting that activation of NF-jB is not
involved. We suspected that VIGR expression might be con-
trolled by other transcription factors, which would be consis-
tent with the lack of VIGR induction by TNFa and IL-1b.
Both, LPS and thrombin have been described to trigger NF-jB
independent signaling pathways. Thrombin can activate gene
expression via the JAK/STAT pathway, via a tyrosine kinase/
DNA-binding protein pathway and via MAP kinase (MAPK)
cascade leading to ERK2/Elk-1 activation [31]. Three MAPK
pathways, JNK, ERK and p38 have been reported to be acti-
vated by LPS in macrophages and the latter two also in HU-
VECs [35]. Therefore we investigated, whether activation of
MAPKs are required for inducible expression of VIGR in re-
sponse to LPS in HUVECs. JNK and MEK1, the latter acti-
vates ERK1/2, MAPK signaling pathways are apparently both
required for LPS-dependent inducible expression of VIGR in
HUVECs, whereas activation of p38 does not result in VIGR
expression. Consistently, analysis of the upstream promoter
region also revealed potential AP-1, Egr-1 and Elk-1 consensus
binding sites, but no NF-jB binding sites. Hence, we consider
MAPKs to be a likely candidate involved in the transcriptional
regulation of VIGR. All three MAPKs function in ECs and
MAPK cross-talk likely plays an important role in EC activa-
tion [36]. The observation that VIGR is highly expressed in
response to both induction of the innate immune response by
LPS, as well as activation of the coagulation system by
thrombin, suggests that VIGR functions at a converging step
common to both pathways.
VIGR is unique because of its novel combination of extra-
cellular adhesion motifs, namely CUB and PTX domains. The
CUB domain is a 110 amino acid residues extracellular do-
main that has been described for the ﬁrst time in complement
subcomponents (C1r/C1s), embryonic sea urchin protein 1
(Uegf) and bone morphogenetic protein 1 (Bmp1). CUB do-
main containing proteins are components and activators of the
complement system, proteases responsible for cleavage of
collagen [37], proteins mediating developmental processes [38],
and even involved in cell-mediated immunity (attractin/DPPT-
L) [39]. CUB domain proteins are either secreted or single
transmembrane domain proteins, thus we report here the ﬁrst
GPCR containing a CUB domain. A recent report demon-
strates, that CUB domain containing proteins are the most
diﬀerentially regulated proteins in Caenorhabditis elegans lar-
val development [40].
PTXs encompass the acute-phase plasma proteins human C-
reactive protein (CRP) and serum amyloid P component.
More recently some neuronal proteins and PTX3 (TSP14)
have been reported to contain PTX domains. Classical PTXs
form pentamers and decamers that show calcium-dependent
binding to a variety of ligands such as bacteria, chromatin and
carbohydrates. Many biological functions have been attributed
to PTXs, including reactivity with the complement system and
with phagocytic leucocytes, suggesting a role in natural host
defense [41]. Noteworthy, PTX3 was demonstrated to be a
pattern recognition receptor for the innate immune system
ﬁghting fungal infections [42].
C. Stehlik et al. / FEBS Letters 569 (2004) 149–155 155Common to CUB and PTX domains is their calcium-de-
pendent binding activity and both domains are linked to im-
mune responses. The CUB domain has been reported to
mediate association between C1s and C1r [43]. SAP forms a
non-covalent complex with the C4b-binding protein, which
regulates the classical complement pathway C3 convertase [44].
CRP was found to bind at the site of complement-induced
injury and is believed to assist in clearance of extracellular
debris during infection and inﬂammation [45]. Therefore it is
tempting to speculate that VIGR might play an important role
in innate immunity and inﬂammation by mediating cell–cell or
cell–extracellular matrix interactions.
Recent evidence also links several adhesion GPCRs to
cancer [6], and therefore, expression levels of VIGR in tumor
cells should be addressed in the future.
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